Find Clinical Trials
Efficacy and safety of 3 doses (0.25, 0.5 and 1mg/day) of agomelatine sublingual administration over an 8-week treatment period, in out-patients with Major Depressive Disorder. An 8-week randomised, double-blind, fixed dose, international multicentre, placebo-controlled study with parallel groups, followed by an extension double-blind treatment period of 16 weeks.
Servier Protocol Code:
CL2-90098-009
Sponsor:
Institut de Recherches Internationales Servier (I.R.I.S)
EudraCT Number:
2009-014045-92
Find a recruiting site
Name:
Institut de Recherches Internationales Servier, Département des études cliniques
Phone number:
+33 1 55 72 60 00
Results
English (USA)Interventions / Treatments
The treatment(s) given to the participants in the study.
- Major Depressive Disorder
- AGOMELATINE
- S090098
Other study id numbers
Other identification numbers the study may be known by.
- CL2-90098-009